Nasdaq Welcomes MyoKardia, Inc. to The Nasdaq Stock Market

NEW YORK, Oct. 29, 2015 (GLOBE NEWSWIRE) — Nasdaq, Inc. (Nasdaq:NDAQ) announced that trading of MyoKardia, Inc. (Nasdaq:MYOK) commenced on The Nasdaq Stock Market on October 29, 2015.

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. MyoKardia’s most advanced product candidate, MYK- 461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM and is currently being evaluated in three Phase 1 clinical trials.

“Launched in 2012, MyoKardia’s focus is on developing treatments for rare cardiovascular diseases that do not currently have targeted therapy options,” said Nelson Griggs, Executive Vice President, Listing Services, Nasdaq. “We are proud to welcome this innovative company to our family of listed companies and look forward to supporting its future success.” 

By listing on Nasdaq, MyoKardia joins many of the world’s largest and most revolutionary companies. Nasdaq is the exchange of choice for 89 percent of healthcare companies that have listed on the U.S. markets year-to-date.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About Nasdaq:

Nasdaq, Inc. (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $8.8 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-

CONTACT: Media Relations Contacts:
Will Briganti
(646) 441-5012
william.briganti@nasdaq.com